NCT05486182

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Patients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 153 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center study in France to evaluate the impact of ESTROTEP PET/CT results on the therapeutic management of patients with metastatic breast cancer (MBC). Each patient will be screened to determine whether the patient meets all the inclusion criteria and none of the exclusion criteria. After inclusion, a standardized pre ESTROTEP PET/CT questionnaire will be completed by the investigators to evaluate the initial management plan. Patient will perform the ESTROTEP PET/CT examination at visit 2. A standardized post ESTROTEP PET/CT questionnaire will then be completed by the investigators. Patients will be followed for 12 months to evaluate their clinical status and standard of care investigations.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	18F Fluoroestradiol Radiopharmaceutical with PET/CT	Administration of one dose of 18F FES for PET/CT imaging

Timeline

• Start date: 2022-02-08
• Primary completion: 2025-04-18
• Completion: 2026-01-01
• First posted: 2022-08-03
• Last updated: 2025-08-14

Locations

11 sites across 1 country: France